Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
13 mars 2025 07h30 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., March 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and...
Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025
06 mars 2025 08h00 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., March 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and...
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications
04 mars 2025 07h30 HE
|
Quoin Pharmaceuticals, Inc.
Target Indications Include Microcystic Lymphatic Malformations, Venous Malformations and AngiofibromasProprietary Invisicare Delivery Technology Designed to Optimize Local Skin Penetration Company...
Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study
27 févr. 2025 07h30 HE
|
Quoin Pharmaceuticals, Inc.
Groundbreaking data from first whole body application of QRX003 underscores potential efficacyTransformational improvement in disease state after just 2 weeks of treatment Clear visual evidence of...
Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome
25 févr. 2025 07h30 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and...
Quoin Pharmaceuticals Launches ‘NETHERTON NOW’ Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure
04 févr. 2025 07h30 HE
|
Quoin Pharmaceuticals, Inc.
Multi-pronged media campaign to raise awareness about the disease and its impact on patients, family members and caregivers.Interactive, stand-alone NETHERTON NOW website launched.Quoin’s QRX003...
Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome
23 janv. 2025 08h30 HE
|
Quoin Pharmaceuticals, Inc.
Four Weeks After Discontinuation of Treatment with QRX003 Complete Reversal of Positive Clinical Improvements Across all Measured Endpoints ObservedData Supports QRX003 Mechanism of Action as a...
Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study
14 janv. 2025 08h30 HE
|
Quoin Pharmaceuticals, Inc.
Continued Significant Improvement in Skin Appearance Observed in StudySubject’s Disease Classification Improved from “Severe” to “Mild” after 6 Weeks Dosing Treatment area expanded from 20% Body...
Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study
06 janv. 2025 08h30 HE
|
Quoin Pharmaceuticals, Inc.
Highly Positive Clinical Data on Completion of Testing for First Subject Dosed Twice Daily with QRX003 in Open-Label StudyDemonstrated Clinical Benefits from QRX003 Observed Across All Measured...
Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering
20 déc. 2024 09h20 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...